Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:IBMNASDAQ:NVDANYSE:RHOTCMKTS:RHHBYOTCMKTS:RHHVFNASDAQ:RXRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIBMInternational Business Machines$262.08-1.8%$244.53$163.53▼$269.28$243.59B0.644.21 million shs1.90 million shsNVDANVIDIA$133.18-0.9%$113.11$86.62▼$195.95$3.27T2.11293.18 million shs149.86 million shsRHRH$197.25-4.9%$197.38$123.03▼$457.26$3.70B2.36972,730 shs386,355 shsRHHBYRoche$39.71+1.1%$39.89$31.19▼$44.31$253.27B0.462.98 million shs1.39 million shsRHHVFRoche$317.63+1.9%$319.19$247.20▼$354.19N/AN/A8,283 shs364 shsRXRXRecursion Pharmaceuticals$4.19-8.0%$5.28$3.79▼$12.36$1.70B0.9913.22 million shs12.03 million shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIBMInternational Business Machines-0.59%+3.18%+11.87%+1.06%+56.91%NVDANVIDIA-0.88%+3.42%+32.62%-3.48%+41.78%RHRH+1.97%-8.09%+29.37%-45.48%-25.86%RHHBYRoche+1.12%+3.57%+2.08%-2.38%+21.18%RHHVFRoche+1.90%+4.30%+1.28%-2.92%+21.03%RXRXRecursion Pharmaceuticals+0.89%+0.89%-17.27%-58.14%-53.48%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIBMInternational Business Machines4.4441 of 5 stars2.33.03.33.53.41.71.9NVDANVIDIA4.8109 of 5 stars3.45.01.73.02.82.51.9RHRH4.3942 of 5 stars4.22.00.01.41.83.31.9RHHBYRocheN/AN/AN/AN/AN/AN/AN/AN/ARHHVFRocheN/AN/AN/AN/AN/AN/AN/AN/ARXRXRecursion Pharmaceuticals2.4429 of 5 stars3.23.00.00.02.42.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIBMInternational Business Machines 2.50Moderate Buy$249.06-4.97% DownsideNVDANVIDIA 2.89Moderate Buy$164.8423.77% UpsideRHRH 2.44Hold$275.9439.89% UpsideRHHBYRoche 2.38HoldN/AN/ARHHVFRoche 0.00N/AN/AN/ARXRXRecursion Pharmaceuticals 2.33Hold$7.6081.60% UpsideCurrent Analyst Ratings BreakdownLatest RXRX, IBM, RH, RHHBY, RHHVF, and NVDA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025IBMInternational Business MachinesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$276.00 ➝ $285.005/14/2025NVDANVIDIABank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$150.00 ➝ $160.005/14/2025RHRHBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetUnderperform ➝ Underperform$144.00 ➝ $172.005/12/2025NVDANVIDIAUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$180.00 ➝ $175.005/10/2025IBMInternational Business MachinesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform5/7/2025IBMInternational Business MachinesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$300.00 ➝ $300.005/6/2025RXRXRecursion PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $8.005/5/2025RHRHThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$276.00 ➝ $194.004/30/2025NVDANVIDIASeaport Res PtnSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong Sell4/28/2025RHHBYRocheHSBCSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold4/28/2025RHHBYRocheHsbc Global ResSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 5/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIBMInternational Business Machines$62.83B3.88$15.36 per share17.06$29.62 per share8.85NVDANVIDIA$130.50B24.96$1.18 per share112.93$1.72 per share77.43RHRH$3.18B1.16$10.34 per share19.07($16.16) per share-12.21RHHBYRoche$68.73B3.69$3.10 per share12.82$5.81 per share6.83RHHVFRocheN/AN/AN/AN/AN/AN/ARXRXRecursion Pharmaceuticals$59.82M28.44N/AN/A$1.98 per share2.11Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIBMInternational Business Machines$6.02B$5.8140.8922.595.819.60%38.99%7.14%7/23/2025 (Estimated)NVDANVIDIA$29.76B$2.9452.5633.461.7655.69%114.83%76.61%5/28/2025 (Estimated)RHRH$127.56M$3.6056.7514.302.652.25%-35.72%2.09%6/12/2025 (Estimated)RHHBYRoche$9.40BN/A0.0013.242.18N/AN/AN/A7/24/2025 (Estimated)RHHVFRocheN/A$10.8129.38∞N/AN/AN/AN/A7/24/2025 (Estimated)RXRXRecursion Pharmaceuticals-$328.07M-$1.77N/AN/AN/A-579.52%-76.56%-55.68%N/ALatest RXRX, IBM, RH, RHHBY, RHHVF, and NVDA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/12/2025Q1 2026RHRH-$0.06N/AN/AN/A$817.66 millionN/A5/28/2025Q1 2026NVDANVIDIA$0.87N/AN/AN/A$43.09 billionN/A5/5/2025Q1 2025RXRXRecursion Pharmaceuticals-$0.44-$0.50-$0.06-$0.50$18.12 million$14.75 million4/23/2025Q1 2025IBMInternational Business Machines$1.42$1.60+$0.18$1.11$14.41 billion$14.54 billion4/2/2025Q4 2025RHRH$1.91$1.58-$0.33$0.69$828.21 million$812.41 million2/28/2025Q4 2024RXRXRecursion Pharmaceuticals-$0.36-$0.53-$0.17-$0.53$19.04 million$4.60 million2/26/2025Q4 2025NVDANVIDIA$0.84$0.89+$0.05$0.89$38.16 billion$39.33 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIBMInternational Business Machines$6.722.56%+0.61%115.66%30 YearsNVDANVIDIA$0.040.03%+33.42%1.36%1 YearsRHRHN/AN/AN/AN/AN/ARHHBYRoche$0.872.19%N/AN/AN/ARHHVFRoche$7.802.46%N/A72.16%N/ARXRXRecursion PharmaceuticalsN/AN/AN/AN/AN/ALatest RXRX, IBM, RH, RHHBY, RHHVF, and NVDA DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/29/2025IBMInternational Business Machinesquarterly$1.682.82%5/9/20256/10/20252/26/2025NVDANVIDIAquarterly$0.010.03%3/12/20253/12/20254/2/20253/21/2025RHHVFRoche$9.703.17%3/27/20253/28/20253/31/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIBMInternational Business Machines1.821.041.00NVDANVIDIA0.134.103.64RHRHN/A1.430.33RHHBYRoche0.861.260.97RHHVFRocheN/AN/AN/ARXRXRecursion Pharmaceuticals0.044.354.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIBMInternational Business Machines58.96%NVDANVIDIA65.27%RHRH90.17%RHHBYRocheN/ARHHVFRoche29.01%RXRXRecursion Pharmaceuticals89.06%Insider OwnershipCompanyInsider OwnershipIBMInternational Business Machines0.18%NVDANVIDIA4.23%RHRH28.10%RHHBYRocheN/ARHHVFRocheN/ARXRXRecursion Pharmaceuticals15.75%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIBMInternational Business Machines311,300929.40 million924.00 millionOptionableNVDANVIDIA26,20024.46 billion23.45 billionOptionableRHRH6,50018.73 million13.38 millionOptionableRHHBYRoche103,6056.38 billionN/ANot OptionableRHHVFRoche103,605N/AN/ANot OptionableRXRXRecursion Pharmaceuticals400406.50 million329.18 millionOptionableRXRX, IBM, RH, RHHBY, RHHVF, and NVDA HeadlinesRecent News About These CompaniesRafferty Asset Management LLC Cuts Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)May 21 at 5:28 AM | marketbeat.comRaiffeisen Bank International AG Buys New Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)May 19 at 6:05 AM | marketbeat.comLazard Asset Management LLC Has $3.76 Million Stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)May 19 at 4:43 AM | marketbeat.comSoftbank Group CORP. Invests $99.15 Million in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)May 18 at 7:17 AM | marketbeat.comRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Bought by Northern Trust CorpMay 17, 2025 | marketbeat.comRecursion Pharmaceuticals, Inc. (RXRX) Nosedives 36.55% As AI Drug Discovery Dreams StallMay 15, 2025 | insidermonkey.comRecursion Pharmaceuticals Plunges 22% in May: How to Play the StockMay 15, 2025 | zacks.comRecursion Pharmaceuticals: High-Risk Play Getting Riskier By The QuarterMay 14, 2025 | seekingalpha.comRecursion Pharmaceuticals, Inc. (RXRX): Among the Best Artificial Intelligence Stocks Under $50 to Buy NowMay 14, 2025 | msn.comLaurion Capital Management LP Invests $16.61 Million in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)May 14, 2025 | marketbeat.comShould You Buy This Beaten-Down Artificial Intelligence (AI) Stock on the Dip?May 12, 2025 | fool.com2 Top Artificial Intelligence (AI) Stocks to Buy Right NowMay 11, 2025 | fool.comLeerink Partnrs Has Bullish Estimate for RXRX Q2 EarningsMay 10, 2025 | marketbeat.comRaymond James Financial Inc. Acquires New Shares in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)May 10, 2025 | marketbeat.comWhy Recursion Pharmaceuticals Stock Plummeted 24% This WeekMay 9, 2025 | fool.com66,900 Shares in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Bought by Bayesian Capital Management LPMay 9, 2025 | marketbeat.comRecursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 5.4% Following Weak EarningsMay 8, 2025 | marketbeat.comRecursion Pharmaceuticals (RXRX) Receives a Hold from TD CowenMay 7, 2025 | theglobeandmail.comNeedham & Company LLC Cuts Recursion Pharmaceuticals (NASDAQ:RXRX) Price Target to $8.00May 7, 2025 | marketbeat.comEarnings Release: Here's Why Analysts Cut Their Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Price Target To US$7.43May 7, 2025 | finance.yahoo.comCasdin Capital LLC Makes New Investment in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)May 7, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBuybacks and Big-Time Developments: 3 Stocks Making Huge MovesBy Leo Miller | May 19, 2025View Buybacks and Big-Time Developments: 3 Stocks Making Huge MovesCan IBM’s Q1 Earnings Spark a Breakout for the Stock?By Jeffrey Neal Johnson | April 23, 2025View Can IBM’s Q1 Earnings Spark a Breakout for the Stock?UnitedHealth Group: Pariah to Pole Position to Buy the Dip LevelsBy Jea Yu | April 22, 2025View UnitedHealth Group: Pariah to Pole Position to Buy the Dip LevelsGenuine Parts: Solid Earnings But Economic Uncertainties RemainBy Chris Markoch | April 23, 2025View Genuine Parts: Solid Earnings But Economic Uncertainties RemainIBM's AI Offensive: Assessing IBM's Path to Renewed GrowthBy Jeffrey Neal Johnson | May 8, 2025View IBM's AI Offensive: Assessing IBM's Path to Renewed GrowthRXRX, IBM, RH, RHHBY, RHHVF, and NVDA Company DescriptionsInternational Business Machines NYSE:IBM$262.08 -4.87 (-1.82%) As of 01:54 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.International Business Machines Corporation, together with its subsidiaries, provides integrated solutions and services worldwide. The company operates through Software, Consulting, Infrastructure, and Financing segments. The Software segment offers a hybrid cloud and AI platforms that allows clients to realize their digital and AI transformations across the applications, data, and environments in which they operate. The Consulting segment focuses on skills integration for strategy, experience, technology, and operations by domain and industry. The Infrastructure segment provides on-premises and cloud based server, and storage solutions, as well as life-cycle services for hybrid cloud infrastructure deployment. The Financing segment offers client and commercial financing, facilitates IBM clients' acquisition of hardware, software, and services. The company has a strategic partnership to various companies including hyperscalers, service providers, global system integrators, and software and hardware vendors that includes Adobe, Amazon Web services, Microsoft, Oracle, Salesforce, Samsung Electronics and SAP, and others. The company was formerly known as Computing-Tabulating-Recording Co. International Business Machines Corporation was incorporated in 1911 and is headquartered in Armonk, New York.NVIDIA NASDAQ:NVDA$133.18 -1.20 (-0.90%) As of 01:54 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.NVIDIA Corporation provides graphics and compute and networking solutions in the United States, Taiwan, China, Hong Kong, and internationally. The Graphics segment offers GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, and solutions for gaming platforms; Quadro/NVIDIA RTX GPUs for enterprise workstation graphics; virtual GPU or vGPU software for cloud-based visual and virtual computing; automotive platforms for infotainment systems; and Omniverse software for building and operating metaverse and 3D internet applications. The Compute & Networking segment comprises Data Center computing platforms and end-to-end networking platforms, including Quantum for InfiniBand and Spectrum for Ethernet; NVIDIA DRIVE automated-driving platform and automotive development agreements; Jetson robotics and other embedded platforms; NVIDIA AI Enterprise and other software; and DGX Cloud software and services. The company's products are used in gaming, professional visualization, data center, and automotive markets. It sells its products to original equipment manufacturers, original device manufacturers, system integrators and distributors, independent software vendors, cloud service providers, consumer internet companies, add-in board manufacturers, distributors, automotive manufacturers and tier-1 automotive suppliers, and other ecosystem participants. NVIDIA Corporation was incorporated in 1993 and is headquartered in Santa Clara, California.RH NYSE:RH$197.25 -10.27 (-4.95%) As of 01:54 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.RH, together with its subsidiaries, operates as a retailer in the home furnishings market. The company offers products in various categories, including furniture, lighting, textiles, bathware, décor, outdoor and garden, baby, child, and teen furnishings. It provides its products through rh.com, rhbabyandchild.com, rhteen.com, rhmodern.com, and waterworks.com online channels, as well as operates RH Galleries, RH outlet stores, RH Guesthouse, and Waterworks showrooms in the United States, Canada, the United Kingdom, and Germany. The company was formerly known as Restoration Hardware Holdings, Inc. and changed its name to RH in January 2017. RH was incorporated in 2011 and is headquartered in Corte Madera, California.Roche OTCMKTS:RHHBY$39.71 +0.44 (+1.12%) As of 05/20/2025 03:59 PM EasternRoche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.Roche OTCMKTS:RHHVF$317.63 +5.93 (+1.90%) As of 05/20/2025 03:21 PM EasternRoche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.Recursion Pharmaceuticals NASDAQ:RXRX$4.18 -0.37 (-8.02%) As of 01:54 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palo Alto Networks: Buy The Dip, Long-Term Tailwinds Ahead Lowe’s Stock Uptrend Can Continue for These 2 Reasons CrowdStrike Near Breakout: Is Now the Time to Buy? Rivian Stock Below $20: Charging Up or in the Breakdown Lane? Viking Holdings Posts Strong Q1, Eyes Growth Ahead 2 Reasons Netflix’s 40% Rally Is Far From Over Qualcomm’s Re-Entry Into the CPU Market May Not Be Enough Applied Digital's Strategic AI Play Gains Momentum Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
